Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
In this study, we present a case of renal failure in a patient who was on a tenofovir-containing regimen, resulting in extremely high tenofovir exposure and prolonged tenofovir monotherapy. We considered this case report important because exposure to tenofovir monotherapy might have consequences for future discontinuation strategies in cases of renal failure.
Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, the Netherlands. Rob@terHeine.nl
Rob
R
Ter Heine
Alwin Dr
AD
Huitema
Robert S
RS
Jansen
Paul Hm
PH
Smits
Eric Cm
EC
van Gorp
Jiri Fp
JF
Wagenaar
Jos H
JH
Beijnen
Jan W
JW
Mulder
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D024882:Drug Resistance, Viral / Q000187:drug effects; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects / Q000493:pharmacokinetics*; D051437:Renal Insufficiency / Q000139:chemically induced*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics; D000068698:Tenofovir; D013997:Time Factors; D028761:Withholding Treatment
D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine